Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis

Mukhtar, Humza; Yasmeen, Uzma; Siddiqa, Sania; Sarfraz, Zouina; Sarfraz, Azza

doi:10.1016/j.msard.2022.104002

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ublituximab-xiiy is an antibody-based disease modifying therapy and monoclonal antibody against the CD20-expressing B-cells (Mukhtar et al 2022 ). Ublituximab is glycoengineered to enhance the antibody-dependent cytotoxicity (Lee et al 2021 ).…”

Section: Neurologymentioning

confidence: 99%

“…Ublituximab has been approved for relapsing forms of multiple sclerosis. Ublituximab is the third approved anti-CD20 multiple sclerosis drug after ocrelizumab and ofatumumab (Mukhtar et al 2022 ). Ublituximab leads to reduced B-cells via cell destruction and prevents immune system–mediated damage to the brain and spinal cord in MS (Margoni et al 2022 ).…”

Section: Neurologymentioning

confidence: 99%

See 1 more Smart Citation

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022

Kaykı-Mutlu

Aksoyalp

Wojnowski

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

While new drug approvals by the U.S. Food and Drug Administration (FDA) had remained stable or even increased in the first 2 years of the COVID-19 pandemic, the 37 newly approved drugs in 2022 are considerably less than the 53 and 50 new drugs approved in 2020 and 2021, respectively, and less than the rolling 10-year average of 43. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify two “first-in-indication” (ganaxolon and teplizumab), 20 (54%) “first-in-class,” and 17 (46%) “next-in-class” drugs. By treatment area, rare diseases and cancer drugs were once again the most prevalent (partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics).

show abstract

Section: Neurologymentioning

confidence: 99%

Section: Neurologymentioning

confidence: 99%